Skip to main content

ETF comparison

IBB vs XLV

Both Healthcare.

iShares Biotechnology ETF · State Street Health Care Select Sector SPDR ETF

Holdings overlap

Weighted by ISIN/CUSIP
11.1 %

9 positions appear in both funds. Buying equal dollars of IBB and XLV would leave roughly 11.1% of each dollar exposed to the same underlying securities.

IBB unmatched 88.8% Shared 11.1% XLV unmatched 88.6%

Unmatched is the part of a fund's weight the other fund doesn't match: names only it holds, plus any extra weight it puts in names both funds hold.

In IBB only
239 positions
Shared
9 positions
In XLV only
51 positions

Side by side

IBB

iShares Biotechnology ETF

iShares · Healthcare

72 composite / 100
Expense ratio
0.44%
Net assets
$11.20B
TTM yield
0.16%
Top-10 conc.
44.7%
XLV

State Street Health Care Select Sector SPDR ETF

State Street · Healthcare

82 composite / 100
Expense ratio
0.080%
Net assets
$43.39B
TTM yield
1.42%
Top-10 conc.
61.5%

Sub-score comparison

56
Cost
92
85
Tax efficiency
83
100
Liquidity
100
50
Concentration
26
—
Tracking quality
—
IBB sub-score XLV

Tracking quality isn't part of the composite — see what we don't score for why.

Cost difference

XLV is 36 bps cheaper than IBB. On a $100,000 position that's about $360/yr more in fees for IBB.

Fee figure is the annual expense charged on $100,000. To see how the gap compounds over a multi-decade holding period, open the cost calculator pre-filled with IBB vs XLV.

Top shared holdings

9 shared in total
# Holding In IBB In XLV Overlap
1 Amgen, Inc. 7.83% 3.40% 3.40%
2 Gilead Sciences, Inc. 6.84% 2.73% 2.73%
3 Vertex Pharmaceuticals, Inc. 8.08% 2.19% 2.19%
4 Regeneron Pharmaceuticals, Inc. 4.91% 1.08% 1.08%
5 Biogen, Inc. 2.47% 0.56% 0.56%
6 Moderna, Inc. 1.98% 0.43% 0.43%
7 Incyte Corp. 1.75% 0.33% 0.33%
8 Bio-Techne Corp. 0.86% 0.19% 0.19%
9 Charles River Laboratories International, Inc. 0.84% 0.19% 0.19%

Only in IBB

239 total
  • Argenx SE 3.76%
  • Alnylam Pharmaceuticals, Inc. 3.12%
  • Natera, Inc. 2.89%
  • Revolution Medicines, Inc. 2.78%
  • Illumina, Inc. 2.07%
  • Insmed, Inc. 1.78%
  • BeOne Medicines Ltd. 1.77%
  • United Therapeutics Corp. 1.73%
  • Roivant Sciences Ltd. 1.43%
  • Neurocrine Biosciences, Inc. 1.30%

Only in XLV

51 total
  • Eli Lilly & Co 16.51%
  • Johnson & Johnson 10.64%
  • AbbVie Inc 7.74%
  • UnitedHealth Group Inc 6.57%
  • Merck & Co Inc 5.52%
  • Thermo Fisher Scientific Inc 3.24%
  • Abbott Laboratories 2.75%
  • Intuitive Surgical Inc 2.45%
  • Pfizer Inc 2.39%
  • CVS Health Corp 2.30%

Percentages are holdings overlap with the named fund.

Open IBB or XLV at a brokerage

Both funds trade commission-free at major US brokerages.

Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.

Holdings overlap is the sum of min(weight_a, weight_b) over positions matched on ISIN (CUSIP fallback). Methodology: see /methodology/.

Comparing two funds doesn't endorse swapping one for the other. Tax-lot history, account type, and personal goals matter — PlainIndex publishes data and methodology, not investment advice.